Polish & Viral Filtration Webinars

31. Virus Filtration: Regulations And Mechanisms 7/25/2024

    In this presentation, Dr. Nigel Jackson, Principal Engineer in R&D, offers an in-depth discussion on regulatory guidance and recent updates pertaining to virus filtration.

32. Simplify And Streamline Processing With SPTFF 6/4/2024

    Are you ready to elevate your bioprocess? Watch to discover how to minimize your system footprint and buffer usage in comparison to TFF with single-pass tangential flow filtration (SPTFF).

33. Be A Gain Changer With 2x Throughput 5/4/2024

    Highly concentrated antibody drugs hold promise in revolutionizing patient treatment. However, new treatments bring forth new challenges in manufacturing. Engineered to deliver the high throughput capacity of high-value drug products, Cytiva Supor™ Prime filters minimize product loss and waste, guaranteeing optimal yield. Watch to learn more about these innovative filters.

34. Osmolality Analysis In Bioprocessing: From Theory To Practice 1/23/2024

    Gain deeper insight into the significant impact of osmolality in bioprocessing and its correlation with immunoglobulin G (IgG) production.

35. Cost Efficient Manufacturing Of Purer AAV Gene Therapy Vectors 12/13/2023

    Review a comparison of the cation exchange and affinity column for the first column step, and learn how the new CIMmultus High Reproducibility (HR) line columns are used for the polishing step.

36. Simplifying EV/Exosome Research & Development 11/6/2023

    Modern solutions are continuing to be developed to help those working in biologics overcome historic Exosomes / Extracellular Vesicles challenges.

37. Therapeutic Market Opportunities For mRNA 10/16/2023

    In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, hundreds of audience members tell us what forms of vaccine and therapeutics they’re developing.

38. Purification Strategies For New Classes Of Antibodies 8/9/2023

    In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses an audience question concerning purification strategies in the growing multi-specific antibody field.

39. Maintaining Downstream Quality In Multi-Specific Antibody Manufacturing 8/9/2023

    Bayer Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses audience questions on downstream multi-specific mAb processing challenges, specifically purification in terms of CPP and QRA, and microbial or thermal degradation, in this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline.

40. Multi-Specific Antibody Development: What Challenges The Need For Speed? 8/9/2023

     

    In this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline, Bayer’s Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses why the industry is pursuing faster, more cost-effective multi-specific antibody development and some of the major challenges standing in the way of efficiency.